Medical Condition News

RSS

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced that the U.S. Food & Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM G3™ SF (Small Fixed), the newest version of its peripheral revascularization catheter for the treatment of PVD.

21 Jun 2010

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed dyslipidemia. LIVALO is available in doses of 1 mg, 2 mg and 4 mg.

21 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. today announced that clinical trial results from the Phase IIb EMBLEM study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism in Rome, Italy.

21 Jun 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

PHCG recognized with CEO Cancer Gold Standard accreditation in fight against cancer

Publicis Healthcare Communications Group, the world's largest healthcare communications group, has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

21 Jun 2010

FDA grants EarlySense marketing clearance for EverOn Touch system

EarlySense announced today that its EverOn Touch system has been cleared for marketing by the U.S. Food and Drug Administration. The FDA clearance covers several key additions to the traditional EverOn contact-free patient supervision system value proposition. For the first time, the EverOn system includes an online display that alerts medical staff regarding a patient's motion level and verifies patient turns as indicated by nurses. Identifying low patient movement and then turning patients methodically are key elements in the prevention of pressure ulcers, the most costly patient safety risk in U.S. hospitals.

21 Jun 2010

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.

21 Jun 2010

Toshiba's Aquilion ONE dynamic volume CT system improves clinical pathway for patients in ERs

Emergency departments are challenged to streamline patient diagnoses and treatment for a variety of conditions and require a CT system capable of imaging patients quickly, accurately and safely. Toshiba America Medical Systems, Inc.'s Aquilion® ONE 320-detector row CT system is designed for such settings and used to evaluate a range of patients, including cardiac, neuro, stroke and pediatric.

21 Jun 2010

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. announced guidance today regarding the Company's planned pivotal Phase III trial for palifosfamide in metastatic soft tissue sarcoma, including details of the proposed study's design, timing and regulatory review.

21 Jun 2010

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Recently, oral cancer survivor Jeanna Richelson, organized the first Chattanooga Oral Cancer Awareness Walk, which raised donations for the Oral Cancer Foundation, and much needed awareness of a disease that too few Americans know about. According to the foundation's executive director Brian Hill, "I don't believe there has ever been an oral cancer walk that was this successful in its first year. This was an absolutely amazing effort by Jeanna and those who helped her make this possible."

21 Jun 2010

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.

21 Jun 2010

FDA accepts ev3's Pipeline Embolization Device PMA for expedited review

ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.

21 Jun 2010

Researchers develop new drugs that relieve cancer pain without side effects

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current pain-treatments like morphine.

21 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites.

21 Jun 2010

Federal funds available to support specialized training curriculum on Mental Health Procedures Act

Approximately $500,000 is available in federal American Recovery and Reinvestment Act funds to support a specialized training curriculum on the Mental Health Procedures Act of 1976 for judges, law enforcement, psychologists, social workers and other professionals in the criminal justice system.

21 Jun 2010

Severity of appendicitis can be predicted from blood sample, shows thesis

The symptoms of appendicitis are often diffuse and it can be difficult to obtain an accurate diagnosis early in the course of the disease. It may be possible to predict the severity from a blood sample, and in this way determine the treatment on an individual basis. This is the conclusion of a thesis presented at the University of Gothenburg, sweden.

21 Jun 2010

Medical Condition News

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

PHCG recognized with CEO Cancer Gold Standard accreditation in fight against cancer

FDA grants EarlySense marketing clearance for EverOn Touch system

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

Toshiba's Aquilion ONE dynamic volume CT system improves clinical pathway for patients in ERs

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

FDA accepts ev3's Pipeline Embolization Device PMA for expedited review

Researchers develop new drugs that relieve cancer pain without side effects

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Federal funds available to support specialized training curriculum on Mental Health Procedures Act

Severity of appendicitis can be predicted from blood sample, shows thesis

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News